probucol has been researched along with Heart Failure in 14 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the preventive effect of probucol combined with hydration on contrast-induced nephropathy (CIN) in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI)." | 9.27 | The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study. ( Cong, H; Fu, N; Liang, M; Lin, W; Lu, C; Tian, F; Yang, S; Zhang, J; Zhang, P, 2018) |
| "In the present study, we examined whether the powerful antioxidant probucol (a clinically used lipid-lowering drug) would attenuate the oxidative stress and energy starvation in experimental model of heart failure (HF) using isoproterenol." | 7.73 | Probucol attenuates oxidative stress and energy decline in isoproterenol-induced heart failure in rat. ( Awad, AS; El-Demerdash, E; El-Hady, AM; Sayed-Ahmed, MM; Taha, RM, 2005) |
| "To investigate the preventive effect of probucol combined with hydration on contrast-induced nephropathy (CIN) in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI)." | 5.27 | The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study. ( Cong, H; Fu, N; Liang, M; Lin, W; Lu, C; Tian, F; Yang, S; Zhang, J; Zhang, P, 2018) |
| "In the present study, we examined whether the powerful antioxidant probucol (a clinically used lipid-lowering drug) would attenuate the oxidative stress and energy starvation in experimental model of heart failure (HF) using isoproterenol." | 3.73 | Probucol attenuates oxidative stress and energy decline in isoproterenol-induced heart failure in rat. ( Awad, AS; El-Demerdash, E; El-Hady, AM; Sayed-Ahmed, MM; Taha, RM, 2005) |
| "At 3 weeks post-treatment duration, ADR caused heart failure which was prevented by probucol." | 3.70 | Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. ( Belló-Klein, A; Danelisen, I; Li, T; Singal, PK, 2000) |
| "Treatment with probucol was also accompanied by an increase in myocardial GSHPx and superoxide dismutase activities, with a concomitant decrease in lipid peroxidation." | 1.29 | Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. ( Kaul, N; Singal, PK; Siveski-Iliskovic, N, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Farahmand, F | 1 |
| Malik, A | 1 |
| Sharma, A | 1 |
| Bagchi, AK | 1 |
| Singal, PK | 7 |
| Fu, N | 1 |
| Yang, S | 1 |
| Zhang, J | 1 |
| Zhang, P | 1 |
| Liang, M | 1 |
| Cong, H | 1 |
| Lin, W | 1 |
| Tian, F | 1 |
| Lu, C | 1 |
| Fukumoto, Y | 1 |
| El-Demerdash, E | 1 |
| Awad, AS | 1 |
| Taha, RM | 1 |
| El-Hady, AM | 1 |
| Sayed-Ahmed, MM | 1 |
| Betge, S | 1 |
| Lutz, K | 1 |
| Roskos, M | 1 |
| Figulla, HR | 1 |
| Recio-Mayoral, A | 1 |
| Kaski, JC | 1 |
| McMurray, JJ | 1 |
| Horowitz, J | 1 |
| van Veldhuisen, DJ | 1 |
| Remme, WJ | 1 |
| Siveski-Iliskovic, N | 2 |
| Hill, M | 1 |
| Thomas, TP | 1 |
| Li, T | 4 |
| Kaul, N | 1 |
| Iliskovic, N | 2 |
| Morishima, I | 1 |
| Matsui, H | 1 |
| Mukawa, H | 1 |
| Hayashi, K | 1 |
| Toki, Y | 1 |
| Okumura, K | 1 |
| Ito, T | 1 |
| Hayakawa, T | 1 |
| Kumar, D | 2 |
| Danelisen, I | 3 |
| Belló-Klein, A | 1 |
| Kirshenbaum, LA | 1 |
| Sia, YT | 1 |
| Lapointe, N | 1 |
| Parker, TG | 1 |
| Tsoporis, JN | 1 |
| Deschepper, CF | 1 |
| Calderone, A | 1 |
| Pourdjabbar, A | 1 |
| Jasmin, JF | 1 |
| Sarrazin, JF | 1 |
| Liu, P | 1 |
| Adam, A | 1 |
| Butany, J | 1 |
| Rouleau, JL | 1 |
2 reviews available for probucol and Heart Failure
| Article | Year |
|---|---|
Combination therapy with probucol prevents adriamycin-induced cardiomyopathy.
Topics: Animals; Antioxidants; Cardiomyopathies; Doxorubicin; Drug Therapy, Combination; Free Radical Scaven | 1995 |
Adriamycin-induced heart failure: mechanism and modulation.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Agents; Apoptosis; Doxorubicin; Drug Therapy, Comb | 2000 |
1 trial available for probucol and Heart Failure
| Article | Year |
|---|---|
The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study.
Topics: Aged; Antioxidants; Combined Modality Therapy; Contrast Media; Coronary Disease; Creatinine; Cystati | 2018 |
11 other studies available for probucol and Heart Failure
| Article | Year |
|---|---|
Role of oxidative stress versus lipids in monocrotaline-induced pulmonary hypertension and right heart failure.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Catalase; Echocardiography; Glutathione Peroxidase; | 2021 |
[Medicines for dyslipidemia].
Topics: Anion Exchange Resins; Arteriosclerosis; Azetidines; Dyslipidemias; Ezetimibe; Fibric Acids; Heart F | 2012 |
Probucol attenuates oxidative stress and energy decline in isoproterenol-induced heart failure in rat.
Topics: Animals; Energy Metabolism; Heart Failure; Heart Rate; Isoproterenol; Male; Myocardium; Oxidative St | 2005 |
Oral treatment with probucol in a pharmacological dose has no beneficial effects on mortality in chronic ischemic heart failure after large myocardial infarction in rats.
Topics: Administration, Oral; Animals; Antioxidants; Chronic Disease; Collagen; Heart Failure; Male; Myocard | 2007 |
Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.
Topics: Abciximab; Acute Coronary Syndrome; Amides; Antibodies, Monoclonal; Benzazepines; Clinical Trials as | 2007 |
Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats.
Topics: Animals; Antioxidants; Doxorubicin; Glutathione Peroxidase; Heart Failure; Hemodynamics; Lipid Perox | 1994 |
Lipid lowering: an important factor in preventing adriamycin-induced heart failure.
Topics: Animals; Anticholesteremic Agents; Doxorubicin; Glutathione Peroxidase; Heart Failure; Hemodynamics; | 1997 |
Melatonin, a pineal hormone with antioxidant property, protects against adriamycin cardiomyopathy in rats.
Topics: Animals; Antibiotics, Antineoplastic; Anticholesteremic Agents; Antioxidants; Doxorubicin; Heart; He | 1998 |
Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats.
Topics: Analysis of Variance; Animals; Anticholesteremic Agents; Antineoplastic Agents; Antioxidants; Blotti | 2000 |
Apoptosis in adriamycin cardiomyopathy and its modulation by probucol.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cardiomyopathies; Caspase 3; | 2001 |
Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat.
Topics: Animals; Antioxidants; Apoptosis; Atrial Natriuretic Factor; Chronic Disease; Disease Models, Animal | 2002 |